Tags

Type your tag names separated by a space and hit enter

Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
Microb Drug Resist. 2018 Jan/Feb; 24(1):35-39.MD

Abstract

In this report, we examined the (1) activity of ceftazidime-avibactam against clinical isolates Klebsiella pneumoniae, including those harboring blaKPC, (2) potential mechanisms leading to reduced susceptibility, and (3) activity of ceftazidime-avibactam when combined with other agents. Of 802 carbapenem-resistant isolates of K. pneumoniae gathered from New York City from 1999 to 2014, all were susceptible to ceftazidime-avibactam. Minimum inhibitory concentrations (MICs) were higher in isolates with K. pneumoniae, with the carbapenemase (KPC)-3 (compared to KPC-2), and those with a frameshift mutation in ompK35. MICs did not appear to be affected by changes in ompK36 or by expression of acrB. Time-kill experiments demonstrated synergy between either polymyxin B or amikacin and ceftazidime-avibactam in a minority of isolates. In conclusion, ceftazidime-avibactam is active against K. pneumoniae, including blaKPC isolates, in our region, but activity is affected by KPC subtype and by mutations in ompK35. Synergy can occur when combined with polymyxin B or amikacin, but is unpredictable.

Authors+Show Affiliations

Division of Infectious Diseases, SUNY-Downstate Medical Center , Brooklyn, New York.Division of Infectious Diseases, SUNY-Downstate Medical Center , Brooklyn, New York.Division of Infectious Diseases, SUNY-Downstate Medical Center , Brooklyn, New York.Division of Infectious Diseases, SUNY-Downstate Medical Center , Brooklyn, New York.Division of Infectious Diseases, SUNY-Downstate Medical Center , Brooklyn, New York.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28590820

Citation

Manning, Nyla, et al. "Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella Pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City." Microbial Drug Resistance (Larchmont, N.Y.), vol. 24, no. 1, 2018, pp. 35-39.
Manning N, Balabanian G, Rose M, et al. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City. Microb Drug Resist. 2018;24(1):35-39.
Manning, N., Balabanian, G., Rose, M., Landman, D., & Quale, J. (2018). Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City. Microbial Drug Resistance (Larchmont, N.Y.), 24(1), 35-39. https://doi.org/10.1089/mdr.2016.0293
Manning N, et al. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella Pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City. Microb Drug Resist. 2018 Jan/Feb;24(1):35-39. PubMed PMID: 28590820.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City. AU - Manning,Nyla, AU - Balabanian,Gregory, AU - Rose,Michael, AU - Landman,David, AU - Quale,John, Y1 - 2017/06/07/ PY - 2017/6/8/pubmed PY - 2018/8/7/medline PY - 2017/6/8/entrez KW - Klebsiella pneumoniae KW - carbapenemase KW - ceftazidime–avibactam SP - 35 EP - 39 JF - Microbial drug resistance (Larchmont, N.Y.) JO - Microb. Drug Resist. VL - 24 IS - 1 N2 - In this report, we examined the (1) activity of ceftazidime-avibactam against clinical isolates Klebsiella pneumoniae, including those harboring blaKPC, (2) potential mechanisms leading to reduced susceptibility, and (3) activity of ceftazidime-avibactam when combined with other agents. Of 802 carbapenem-resistant isolates of K. pneumoniae gathered from New York City from 1999 to 2014, all were susceptible to ceftazidime-avibactam. Minimum inhibitory concentrations (MICs) were higher in isolates with K. pneumoniae, with the carbapenemase (KPC)-3 (compared to KPC-2), and those with a frameshift mutation in ompK35. MICs did not appear to be affected by changes in ompK36 or by expression of acrB. Time-kill experiments demonstrated synergy between either polymyxin B or amikacin and ceftazidime-avibactam in a minority of isolates. In conclusion, ceftazidime-avibactam is active against K. pneumoniae, including blaKPC isolates, in our region, but activity is affected by KPC subtype and by mutations in ompK35. Synergy can occur when combined with polymyxin B or amikacin, but is unpredictable. SN - 1931-8448 UR - https://www.unboundmedicine.com/medline/citation/28590820/Activity_of_Ceftazidime_Avibactam_Against_Clinical_Isolates_of_Klebsiella_pneumoniae_Including_KPC_Carrying_Isolates_Endemic_to_New_York_City_ L2 - https://www.liebertpub.com/doi/full/10.1089/mdr.2016.0293?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -